AB Science Raises €2.3 Million to Fund Oncology and ALS Programs

Funding Linked to Ongoing Trials

The private placement involved the issuance of 3.475 million new shares without preferential subscription rights, priced at €0.66 per share (including premium). Each share comes with a warrant (BSA) allowing the holder to subsequently subscribe to an ordinary share at a price of €0.93. The BSAs can be exercised within 60 months of their issuance and represent a potential revenue of €3.2 million if all are converted.

AB Science stated that the proceeds from the placement 'will provide the Company with additional resources necessary to fund its research and development programs,' covering its needs beyond the next 12 months. The group focuses on AB8939 in acute myeloid leukemia and masitinib in amyotrophic lateral sclerosis as priorities.

Limited Dilutive Impact on Shareholding

The issuance represents 4.54% of the equity on a non-diluted basis before the placement, and 4.34% afterwards. For reference, a shareholder holding 1% of the capital before the transaction and not participating would see their stake reduced to 0.9566% on a non-diluted basis after the placement.

The discount applied to the issue price is set at 24.23% compared to the volume-weighted average of the three trading days prior to the price setting (June 26-30). The settlement-delivery of the shares is scheduled for July 6, 2026, with listing on Euronext Paris the following day.

Standstill and Lock-up Commitments from Executives

AB Science has signed a 45-calendar-day standstill commitment starting from the settlement-delivery of the placement. The executives and directors have committed to the investors to observe a 90-calendar-day holding period, subject to customary exceptions. Maxim Group, LLC acted as the placement agent.